Panitumumab is an epidermal growth factor receptor antagonist indicated for the treatment of adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*. MedsAcross supplies Panitumumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*: In combination with FOLFOX for first-line treatment. As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
Source: US FDA prescribing information
The EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases, including EGFR, HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues, including the skin and hair follicle. EGFR is overexpressed in certain human cancers, including colon and rectum cancers. Interaction of EGFR with its normal ligands (e.g., EGF, transforming growth factor-alpha) leads to phosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genes involved with cellular growth and survival, motility, and proliferation. KRAS (Kirsten rat sarcoma 2 viral oncogene homologue) and NRAS (Neuroblastoma RAS viral oncogene homologue) are highly related members of the RAS oncogene family.
Source: US FDA prescribing information
RAS Wild-Type mCRC: Administer 6 mg/kg every 14 days as an intravenous infusion over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg). KRAS G12C -mutated mCRC: Administer 6 mg/kg every 14 days as an intravenous infusion over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) in combination with sotorasib.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Boxed warning (dermatologic toxicity): Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy. WARNING: DERMATOLOGIC TOXICITY. Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy. Dermatologic and Soft Tissue Toxicity: Monitor for dermatologic and soft tissue toxicities. Reduce dose for recurrent Grade 3 toxicity and withhold or discontinue Vectibix for severe or life-threatening complications. Limit sun exposure. Increased tumor progression, increased mortality, or lack of benefit in patients with RAS -mutant mCRC, receiving Vectibix monotherapy or in combination with oxaliplatin-based chemotherapy. Electrolyte Depletion/Monitoring: Monitor electrolytes and institute appropriate treatment.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the label: Dermatologic and Soft Tissue Toxicity Increased Tumor Progression, Increased Mortality, or Lack of Benefit in Patients with RAS -Mutant mCRC Receiving Vectibix Monotherapy or in Combination with Oxaliplatin-based Chemotherapy Electrolyte Depletion/Monitoring Infusion Reactions Acute Renal Failure Pulmonary Fibrosis/Interstitial Lung Disease (ILD) Photosensitivity Ocular Toxicities Increased Mortality and Toxicity with Vectibix in combination with Bevacizumab and Chemotherapy Most common adverse reactions (≥ 20%) of Vectibix as monotherapy are skin rash with variable presentations, paronychia, fatigue, nausea, and diarrhea.
Source: US FDA prescribing information
Store vials in the original carton under refrigeration at 2° to 8°C (36° to 46°F) until time of use. Do not freeze or shake. Protect from direct sunlight.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Panitumumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vectibix 100 mg/5 mL injectionIntravenous Cold chain | Amgen | US FDA | Available on request |
| Vectibix 400 mg/20 mL injectionIntravenous Cold chain | Amgen | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Panitumumab in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Panitumumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Panitumumab, including Vectibix.
Yes. The US FDA first approved Panitumumab on 27 September 2006, according to Drugs@FDA.
Yes. Panitumumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Panitumumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Panitumumab is classified under ATC code L01XC08 (Panitumumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.